Sigrid Juselius Foundation Report issue

Foundation Phase 1 Phase 3

Organization Overview

First Clinical Trial
2013
NCT01880827
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2013

Timeline

NOW
  • Now

Alternative names

Sigrid Juselius Foundation, Helsinki, Finland

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Diabetes Mellitus, Type 2 (Phase 1)

Obesity (Phase 1)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 2
  • # of Trial APIs: 5